{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T02:52:07Z","timestamp":1793760727416,"version":"4.6.1"},"reference-count":80,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,5,26]],"date-time":"2021-05-26T00:00:00Z","timestamp":1621987200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004330","name":"GlaxoSmithKline","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004330","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006259","name":"Teva Pharmaceutical Industries","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006259","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008349","name":"Boehringer Ingelheim","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008349","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","mayoclinicproceedings.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Mayo Clinic Proceedings"],"published-print":{"date-parts":[[2021,10]]},"DOI":"10.1016\/j.mayocp.2021.04.025","type":"journal-article","created":{"date-parts":[[2021,9,15]],"date-time":"2021-09-15T07:52:30Z","timestamp":1631692350000},"page":"2694-2707","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":304,"title":["Eosinophils in Health and Disease: A State-of-the-Art Review"],"prefix":"10.1016","volume":"96","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3505-2946","authenticated-orcid":false,"given":"Michael E.","family":"Wechsler","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ariel","family":"Munitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven J.","family":"Ackerman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew G.","family":"Drake","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David J.","family":"Jackson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew J.","family":"Wardlaw","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie K.","family":"Dougan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sergejs","family":"Berdnikovs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florence","family":"Schleich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Matucci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pascal","family":"Chanez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charlene M.","family":"Prazma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Howarth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9580-560X","authenticated-orcid":false,"given":"Peter F.","family":"Weller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter A.","family":"Merkel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.mayocp.2021.04.025_bib1","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1146\/annurev-pathmechdis-012419-032756","article-title":"Contributions of eosinophils to human health and disease","volume":"15","author":"Klion","year":"2020","journal-title":"Annu Rev Pathol"},{"issue":"1","key":"10.1016\/j.mayocp.2021.04.025_bib2","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1002\/JLB.1MR1117-442RR","article-title":"Shaping eosinophil identity in the tissue contexts of development, homeostasis, and disease","volume":"104","author":"Abdala-Valencia","year":"2018","journal-title":"J\u00a0Leukoc Biol"},{"key":"10.1016\/j.mayocp.2021.04.025_bib3","doi-asserted-by":"crossref","first-page":"93","DOI":"10.3389\/fmed.2017.00093","article-title":"The biology of eosinophils and their role in asthma","volume":"4","author":"McBrien","year":"2017","journal-title":"Front Med (Lausanne)"},{"issue":"2","key":"10.1016\/j.mayocp.2021.04.025_bib4","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1111\/cea.12880","article-title":"Revisiting type 2\u2013high and type 2\u2013low airway inflammation in asthma: current knowledge and therapeutic implications","volume":"47","author":"Robinson","year":"2017","journal-title":"Clin Exp Allergy"},{"key":"10.1016\/j.mayocp.2021.04.025_bib5","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.12688\/f1000research.11133.1","article-title":"Recent advances in understanding eosinophil biology","volume":"6","author":"Klion","year":"2017","journal-title":"F1000Res"},{"issue":"25","key":"10.1016\/j.mayocp.2021.04.025_bib6","doi-asserted-by":"crossref","first-page":"17406","DOI":"10.1074\/jbc.R113.546218","article-title":"Eosinophil granule proteins: form and function","volume":"289","author":"Acharya","year":"2014","journal-title":"J\u00a0Biol Chem"},{"issue":"27","key":"10.1016\/j.mayocp.2021.04.025_bib7","doi-asserted-by":"crossref","first-page":"3503","DOI":"10.3748\/wjg.v25.i27.3503","article-title":"Eosinophils in the gastrointestinal tract and their role in the pathogenesis of major colorectal disorders","volume":"25","author":"Loktionov","year":"2019","journal-title":"World J Gastroenterol"},{"issue":"20","key":"10.1016\/j.mayocp.2021.04.025_bib8","doi-asserted-by":"crossref","first-page":"2183","DOI":"10.1182\/blood-2018-04-842260","article-title":"Charcot-Leyden crystal formation is closely associated with eosinophil extracellular trap cell death","volume":"132","author":"Ueki","year":"2018","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.mayocp.2021.04.025_bib9","first-page":"1341","article-title":"Piecemeal degranulation in human eosinophils: a distinct secretion mechanism underlying inflammatory responses","volume":"25","author":"Melo","year":"2010","journal-title":"Histol Histopathol"},{"issue":"6442","key":"10.1016\/j.mayocp.2021.04.025_bib10","doi-asserted-by":"crossref","first-page":"eaaw4295","DOI":"10.1126\/science.aaw4295","article-title":"Protein crystallization promotes type 2 immunity and is reversible by antibody treatment","volume":"364","author":"Persson","year":"2019","journal-title":"Science"},{"issue":"10","key":"10.1016\/j.mayocp.2021.04.025_bib11","doi-asserted-by":"crossref","first-page":"3961","DOI":"10.4049\/jimmunol.144.10.3961","article-title":"Eosinophil degranulation. An immunologic determinant in the pathogenesis of the Mazzotti reaction in human onchocerciasis","volume":"144","author":"Ackerman","year":"1990","journal-title":"J\u00a0Immunol"},{"issue":"5","key":"10.1016\/j.mayocp.2021.04.025_bib12","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1089\/vim.2018.0150","article-title":"Eosinophils and respiratory viruses","volume":"32","author":"Flores-Torres","year":"2019","journal-title":"Viral Immunol"},{"issue":"8","key":"10.1016\/j.mayocp.2021.04.025_bib13","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1038\/s42255-020-0228-3","article-title":"Eosinophils regulate adipose tissue inflammation and sustain physical and immunological fitness in old age","volume":"2","author":"Brigger","year":"2020","journal-title":"Nat Metab"},{"issue":"1","key":"10.1016\/j.mayocp.2021.04.025_bib14","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1002\/JLB.3MR1117-426R","article-title":"Eosinophil and airway nerve interactions in asthma","volume":"104","author":"Drake","year":"2018","journal-title":"J\u00a0Leukoc Biol"},{"issue":"12","key":"10.1016\/j.mayocp.2021.04.025_bib15","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1038\/nri.2017.95","article-title":"Functions of tissue-resident eosinophils","volume":"17","author":"Weller","year":"2017","journal-title":"Nat Rev Immunol"},{"issue":"9","key":"10.1016\/j.mayocp.2021.04.025_bib16","doi-asserted-by":"crossref","first-page":"3279","DOI":"10.1172\/JCI85664","article-title":"Lung-resident eosinophils represent a distinct regulatory eosinophil subset","volume":"126","author":"Mesnil","year":"2016","journal-title":"J\u00a0Clin Invest"},{"issue":"6","key":"10.1016\/j.mayocp.2021.04.025_bib17","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.1016\/j.cell.2014.11.018","article-title":"Tissue-resident macrophage enhancer landscapes are shaped by the local microenvironment","volume":"159","author":"Lavin","year":"2014","journal-title":"Cell"},{"issue":"5","key":"10.1016\/j.mayocp.2021.04.025_bib18","doi-asserted-by":"crossref","first-page":"1901874","DOI":"10.1183\/13993003.01874-2019","article-title":"Blood eosinophil count in the general population: typical values and potential confounders","volume":"55","author":"Hartl","year":"2020","journal-title":"Eur Respir J"},{"issue":"26","key":"10.1016\/j.mayocp.2021.04.025_bib19","doi-asserted-by":"crossref","first-page":"2486","DOI":"10.1056\/NEJMoa1804092","article-title":"Dupilumab efficacy and safety in moderate-to-severe uncontrolled asthma","volume":"378","author":"Castro","year":"2018","journal-title":"N\u00a0Engl J Med"},{"issue":"5","key":"10.1016\/j.mayocp.2021.04.025_bib20","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/S2213-2600(15)00042-9","article-title":"Reslizumab for inadequately controlled asthma with elevated blood eosinophil counts: results from two multicentre, parallel, double-blind, randomised, placebo-controlled, phase 3 trials [erratum appears in Lancet Respir Med. 2015;3(4):e15]","volume":"3","author":"Castro","year":"2015","journal-title":"Lancet Respir Med"},{"issue":"10056","key":"10.1016\/j.mayocp.2021.04.025_bib21","doi-asserted-by":"crossref","first-page":"2128","DOI":"10.1016\/S0140-6736(16)31322-8","article-title":"Benralizumab, an anti\u2013interleukin-5 receptor \u03b1 monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3 trial","volume":"388","author":"FitzGerald","year":"2016","journal-title":"Lancet"},{"issue":"13","key":"10.1016\/j.mayocp.2021.04.025_bib22","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1056\/NEJMoa1403290","article-title":"Mepolizumab treatment in patients with severe eosinophilic asthma [erratum appears in N Engl J Med. 2015;372(18):1777]","volume":"371","author":"Ortega","year":"2014","journal-title":"N\u00a0Engl J Med"},{"issue":"3","key":"10.1016\/j.mayocp.2021.04.025_bib23","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1111\/j.1398-9995.2004.00772.x","article-title":"Benefits of omalizumab as add-on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment): INNOVATE","volume":"60","author":"Humbert","year":"2005","journal-title":"Allergy"},{"issue":"10209","key":"10.1016\/j.mayocp.2021.04.025_bib24","doi-asserted-by":"crossref","first-page":"1638","DOI":"10.1016\/S0140-6736(19)31881-1","volume":"394","author":"Bachert","year":"2019","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.mayocp.2021.04.025_bib25","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1016\/j.jaci.2020.05.032","article-title":"Efficacy and safety of omalizumab in nasal polyposis: 2 randomized phase 3 trials [erratum appears in J Allergy Clin Immunol. 2021;147(1):416]","volume":"146","author":"Gevaert","year":"2020","journal-title":"J\u00a0Allergy Clin Immunol"},{"issue":"suppl 64","key":"10.1016\/j.mayocp.2021.04.025_bib26","first-page":"4616","article-title":"Add-on mepolizumab for chronic rhinosinusitis with nasal polyps: SYNAPSE study","volume":"56","author":"Hopkins","year":"2020","journal-title":"Eur Respir J"},{"issue":"17","key":"10.1016\/j.mayocp.2021.04.025_bib27","doi-asserted-by":"crossref","first-page":"1613","DOI":"10.1056\/NEJMoa1708208","article-title":"Mepolizumab for eosinophilic chronic obstructive pulmonary disease","volume":"377","author":"Pavord","year":"2017","journal-title":"N\u00a0Engl J Med"},{"issue":"2","key":"10.1016\/j.mayocp.2021.04.025_bib28","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/S2213-2600(19)30338-8","article-title":"Predicting response to benralizumab in chronic obstructive pulmonary disease: analyses of GALATHEA and TERRANOVA studies","volume":"8","author":"Criner","year":"2020","journal-title":"Lancet Respir Med"},{"issue":"20","key":"10.1016\/j.mayocp.2021.04.025_bib29","doi-asserted-by":"crossref","first-page":"1921","DOI":"10.1056\/NEJMoa1702079","article-title":"Mepolizumab or placebo for eosinophilic granulomatosis with polyangiitis","volume":"376","author":"Wechsler","year":"2017","journal-title":"N\u00a0Engl J Med"},{"issue":"3","key":"10.1016\/j.mayocp.2021.04.025_bib30","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.1016\/j.jaip.2020.09.054","article-title":"Benralizumab as a steroid-sparing treatment option in eosinophilic granulomatosis with polyangiitis","volume":"9","author":"Guntur","year":"2021","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"issue":"6","key":"10.1016\/j.mayocp.2021.04.025_bib31","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1016\/j.jaci.2020.08.037","article-title":"Efficacy and safety of mepolizumab in hypereosinophilic syndrome: a phase III, randomized, placebo-controlled trial","volume":"146","author":"Roufosse","year":"2020","journal-title":"J\u00a0Allergy Clin Immunol"},{"issue":"14","key":"10.1016\/j.mayocp.2021.04.025_bib32","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.1056\/NEJMoa1812185","article-title":"Benralizumab for PDGFRA-negative hypereosinophilic syndrome","volume":"380","author":"Kuang","year":"2019","journal-title":"N\u00a0Engl J Med"},{"issue":"1","key":"10.1016\/j.mayocp.2021.04.025_bib33","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1136\/gut.2009.178558","article-title":"Anti\u2013interleukin-5 antibody treatment (mepolizumab) in active eosinophilic oesophagitis: a randomised, placebo-controlled, double-blind trial","volume":"59","author":"Straumann","year":"2010","journal-title":"Gut"},{"issue":"2","key":"10.1016\/j.mayocp.2021.04.025_bib34","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1016\/j.jaci.2011.11.044","article-title":"Reslizumab in children and adolescents with eosinophilic esophagitis: results of a double-blind, randomized, placebo-controlled trial","volume":"129","author":"Spergel","year":"2012","journal-title":"J\u00a0Allergy Clin Immunol"},{"issue":"1","key":"10.1016\/j.mayocp.2021.04.025_bib35","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1053\/j.gastro.2019.09.042","article-title":"Efficacy of dupilumab in a phase 2 randomized trial of adults with active eosinophilic esophagitis","volume":"158","author":"Hirano","year":"2020","journal-title":"Gastroenterology"},{"issue":"3","key":"10.1016\/j.mayocp.2021.04.025_bib36","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1053\/j.gastro.2018.10.051","article-title":"RPC4046, a monoclonal antibody against IL13, reduces histologic and endoscopic activity in patients with eosinophilic esophagitis","volume":"156","author":"Hirano","year":"2019","journal-title":"Gastroenterology"},{"issue":"2, suppl","key":"10.1016\/j.mayocp.2021.04.025_bib37","doi-asserted-by":"crossref","first-page":"AB167","DOI":"10.1016\/j.jaci.2019.12.343","article-title":"AK002, an anti\u2013siglec-8 antibody, depletes tissue eosinophils and improves dysphagia symptoms in patients with eosinophilic esophagitis","volume":"145","author":"Hirano","year":"2020","journal-title":"J\u00a0Allergy Clin Immunol"},{"issue":"17","key":"10.1016\/j.mayocp.2021.04.025_bib38","doi-asserted-by":"crossref","first-page":"1624","DOI":"10.1056\/NEJMoa2012047","article-title":"Anti\u2013siglec-8 antibody for eosinophilic gastritis and duodenitis","volume":"383","author":"Dellon","year":"2020","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.mayocp.2021.04.025_bib39","doi-asserted-by":"crossref","first-page":"1514","DOI":"10.3389\/fphys.2019.01514","article-title":"Interleukin-5 in the pathophysiology of severe asthma","volume":"10","author":"Pelaia","year":"2019","journal-title":"Front Physiol"},{"issue":"5","key":"10.1016\/j.mayocp.2021.04.025_bib40","doi-asserted-by":"crossref","first-page":"1742","DOI":"10.1016\/j.jaci.2018.09.033","article-title":"Assessment of the long-term safety of mepolizumab and durability of clinical response in patients with severe eosinophilic asthma","volume":"143","author":"Khatri","year":"2019","journal-title":"J\u00a0Allergy Clin Immunol"},{"issue":"6","key":"10.1016\/j.mayocp.2021.04.025_bib41","doi-asserted-by":"crossref","first-page":"1572","DOI":"10.1016\/j.jaip.2017.08.024","article-title":"Long-term safety and efficacy of reslizumab in patients with eosinophilic asthma\u00a0[erratum appears in J Allergy Clin Immunol Pract. 2018;6(3):1095]","volume":"5","author":"Murphy","year":"2017","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"issue":"3","key":"10.1016\/j.mayocp.2021.04.025_bib42","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.4049\/jimmunol.182.3.1577","article-title":"Eosinophil deficiency compromises parasite survival in chronic nematode infection","volume":"182","author":"Fabre","year":"2009","journal-title":"J\u00a0Immunol"},{"issue":"3","key":"10.1016\/j.mayocp.2021.04.025_bib43","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1165\/ajrcmb.13.3.7654390","article-title":"Involvement of IL-5 in a murine model of allergic pulmonary inflammation: prophylactic and therapeutic effect of an anti\u2013IL-5 antibody","volume":"13","author":"Kung","year":"1995","journal-title":"Am J Respir Cell Mol Biol"},{"issue":"2","key":"10.1016\/j.mayocp.2021.04.025_bib44","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1164\/ajrccm.152.2.7633694","article-title":"Effects of an antibody to interleukin-5 in a monkey model of asthma","volume":"152","author":"Mauser","year":"1995","journal-title":"Am J Respir Crit Care Med"},{"issue":"7","key":"10.1016\/j.mayocp.2021.04.025_bib45","doi-asserted-by":"crossref","first-page":"2770","DOI":"10.1128\/IAI.00931-10","article-title":"Major basic protein from eosinophils and myeloperoxidase from neutrophils are required for protective immunity to Strongyloides stercoralis in mice","volume":"79","author":"O'Connell","year":"2011","journal-title":"Infect Immun"},{"issue":"7","key":"10.1016\/j.mayocp.2021.04.025_bib46","doi-asserted-by":"crossref","first-page":"2420","DOI":"10.1182\/blood-2006-04-015933","article-title":"Schistosoma mansoni infection in eosinophil lineage\u2013ablated mice","volume":"108","author":"Swartz","year":"2006","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.mayocp.2021.04.025_bib47","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1183\/09031936.00202013","article-title":"International ERS\/ATS guidelines on definition, evaluation and treatment of severe asthma [erratum appears in Eur Respir J. 2014;43(4):1216]","volume":"43","author":"Chung","year":"2014","journal-title":"Eur Respir J"},{"issue":"6","key":"10.1016\/j.mayocp.2021.04.025_bib48","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1016\/j.jaci.2017.10.005","article-title":"Biomarkers for severe eosinophilic asthma","volume":"140","author":"Yancey","year":"2017","journal-title":"J\u00a0Allergy Clin Immunol"},{"issue":"11","key":"10.1016\/j.mayocp.2021.04.025_bib49","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1016\/S2213-2600(15)00367-7","article-title":"Blood eosinophil count and prospective annual asthma disease burden: a UK cohort study","volume":"3","author":"Price","year":"2015","journal-title":"Lancet Respir Med"},{"issue":"3, suppl","key":"10.1016\/j.mayocp.2021.04.025_bib50","doi-asserted-by":"crossref","first-page":"S9","DOI":"10.1016\/j.jaci.2011.12.979","article-title":"Asthma outcomes: biomarkers","volume":"129","author":"Szefler","year":"2012","journal-title":"J\u00a0Allergy Clin Immunol"},{"issue":"5","key":"10.1016\/j.mayocp.2021.04.025_bib51","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1164\/rccm.202004-1013ED","article-title":"Blood eosinophil-directed management of airway disease. The past, present, and future","volume":"202","author":"Pavord","year":"2020","journal-title":"Am J Respir Crit Care Med"},{"issue":"5","key":"10.1016\/j.mayocp.2021.04.025_bib52","doi-asserted-by":"crossref","first-page":"1902420","DOI":"10.1183\/13993003.02420-2019","article-title":"Mepolizumab effectiveness and identification of super-responders in severe asthma","volume":"55","author":"Harvey","year":"2020","journal-title":"Eur Respir J"},{"issue":"1","key":"10.1016\/j.mayocp.2021.04.025_bib53","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1183\/09031936.00201813","article-title":"Importance of concomitant local and systemic eosinophilia in uncontrolled asthma","volume":"44","author":"Schleich","year":"2014","journal-title":"Eur Respir J"},{"issue":"9","key":"10.1016\/j.mayocp.2021.04.025_bib54","doi-asserted-by":"crossref","first-page":"715","DOI":"10.2217\/bmm-2018-0280","article-title":"Charcot-Leyden crystal protein\/galectin-10 is a surrogate biomarker of eosinophilic airway inflammation in asthma","volume":"13","author":"Nyenhuis","year":"2019","journal-title":"Biomark Med"},{"issue":"1","key":"10.1016\/j.mayocp.2021.04.025_bib55","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1164\/rccm.201707-1323OC","article-title":"Weight-adjusted intravenous reslizumab in severe asthma with inadequate response to fixed-dose subcutaneous mepolizumab","volume":"197","author":"Mukherjee","year":"2018","journal-title":"Am J Respir Crit Care Med"},{"issue":"8","key":"10.1016\/j.mayocp.2021.04.025_bib56","doi-asserted-by":"crossref","first-page":"2085","DOI":"10.1111\/all.14266","article-title":"Eosinophil-derived neurotoxin and clinical outcomes with mepolizumab in severe eosinophilic asthma","volume":"75","author":"Howarth","year":"2020","journal-title":"Allergy"},{"issue":"7","key":"10.1016\/j.mayocp.2021.04.025_bib57","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1111\/cea.13680","article-title":"Fungal sensitization and its relationship to mepolizumab response in patients with severe eosinophilic asthma","volume":"50","author":"Wardlaw","year":"2020","journal-title":"Clin Exp Allergy"},{"issue":"7","key":"10.1016\/j.mayocp.2021.04.025_bib58","doi-asserted-by":"crossref","first-page":"2412","DOI":"10.1016\/j.jaip.2020.03.023","article-title":"Mepolizumab for allergic bronchopulmonary aspergillosis: report of 20 cases from the Belgian Severe Asthma Registry and review of the literature","volume":"8","author":"Schleich","year":"2020","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"issue":"2","key":"10.1016\/j.mayocp.2021.04.025_bib59","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1007\/s00408-020-00336-3","article-title":"Real-life study of mepolizumab in idiopathic chronic eosinophilic pneumonia","volume":"198","author":"Brenard","year":"2020","journal-title":"Lung"},{"issue":"2","key":"10.1016\/j.mayocp.2021.04.025_bib60","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/j.jaci.2020.01.013","article-title":"Charcot-Leyden crystal protein\/galectin-10 interacts with cationic ribonucleases and is required for eosinophil granulogenesis","volume":"146","author":"Grozdanovic","year":"2020","journal-title":"J\u00a0Allergy Clin Immunol"},{"issue":"3","key":"10.1016\/j.mayocp.2021.04.025_bib61","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1172\/JCI95693","article-title":"Mucus plugs in patients with asthma linked to eosinophilia and airflow obstruction","volume":"128","author":"Dunican","year":"2018","journal-title":"J\u00a0Clin Invest"},{"issue":"1","key":"10.1016\/j.mayocp.2021.04.025_bib62","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/j.jaci.2019.03.029","article-title":"Charcot-Leyden crystal concentration in nasal secretions predicts clinical response to glucocorticoids in patients with chronic rhinosinusitis with nasal polyps","volume":"144","author":"Wu","year":"2019","journal-title":"J\u00a0Allergy Clin Immunol"},{"issue":"2","key":"10.1016\/j.mayocp.2021.04.025_bib63","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1007\/s12016-015-8506-7","article-title":"Hypereosinophilic syndrome","volume":"50","author":"Curtis","year":"2016","journal-title":"Clin Rev Allergy Immunol"},{"issue":"4","key":"10.1016\/j.mayocp.2021.04.025_bib64","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1016\/j.alit.2019.06.004","article-title":"Update on eosinophilic granulomatosis with polyangiitis","volume":"68","author":"Furuta","year":"2019","journal-title":"Allergol Int"},{"key":"10.1016\/j.mayocp.2021.04.025_bib65","doi-asserted-by":"crossref","first-page":"549","DOI":"10.3389\/fimmu.2014.00549","article-title":"Eosinophilic granulomatosis with polyangiitis: an overview","volume":"5","author":"Gioffredi","year":"2014","journal-title":"Front Immunol"},{"issue":"6","key":"10.1016\/j.mayocp.2021.04.025_bib66","doi-asserted-by":"crossref","first-page":"2170","DOI":"10.1016\/j.jaci.2018.11.041","article-title":"Evaluation of clinical benefit from treatment with mepolizumab for patients with eosinophilic granulomatosis with polyangiitis","volume":"143","author":"Steinfeld","year":"2019","journal-title":"J\u00a0Allergy Clin Immunol"},{"issue":"suppl","key":"10.1016\/j.mayocp.2021.04.025_bib67","first-page":"1797","article-title":"Different disease subtypes in allergic eosinophilic granulomatosis with polyangiitis (EGPA)","volume":"42","author":"Latorre","year":"2013","journal-title":"Eur Respir J"},{"issue":"2","key":"10.1016\/j.mayocp.2021.04.025_bib68","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/j.anai.2018.06.013","article-title":"Eosinophilic gastrointestinal diseases beyond eosinophilic esophagitis","volume":"121","author":"Egan","year":"2018","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"2","key":"10.1016\/j.mayocp.2021.04.025_bib69","doi-asserted-by":"crossref","first-page":"e1393134","DOI":"10.1080\/2162402X.2017.1393134","article-title":"Eosinophils: the unsung heroes in cancer?","volume":"7","author":"Varricchi","year":"2018","journal-title":"Oncoimmunology"},{"issue":"10","key":"10.1016\/j.mayocp.2021.04.025_bib70","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1038\/s41568-020-0283-9","article-title":"A\u00a0new dawn for eosinophils in the tumour microenvironment","volume":"20","author":"Grisaru-Tal","year":"2020","journal-title":"Nat Rev Cancer"},{"issue":"3","key":"10.1016\/j.mayocp.2021.04.025_bib71","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1158\/2326-6066.CIR-18-0494","article-title":"Activated eosinophils exert antitumorigenic activities in colorectal cancer","volume":"7","author":"Reichman","year":"2019","journal-title":"Cancer Immunol Res"},{"issue":"6","key":"10.1016\/j.mayocp.2021.04.025_bib72","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1038\/ni.3159","article-title":"Eosinophils orchestrate cancer rejection by normalizing tumor vessels and enhancing infiltration of CD8+ T cells [erratum appears in Nat Immunol. 2016;17(2):214]","volume":"16","author":"Carretero","year":"2015","journal-title":"Nat Immunol"},{"issue":"4","key":"10.1016\/j.mayocp.2021.04.025_bib73","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1016\/j.immuni.2019.03.022","article-title":"GM-CSF, IL-3, and IL-5 family of cytokines: regulators of inflammation","volume":"50","author":"Dougan","year":"2019","journal-title":"Immunity"},{"issue":"9","key":"10.1016\/j.mayocp.2021.04.025_bib74","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1038\/s41590-020-0745-y","article-title":"ILC2-driven innate immune checkpoint mechanism antagonizes NK cell antimetastatic function in the lung","volume":"21","author":"Schuijs","year":"2020","journal-title":"Nat Immunol"},{"issue":"10","key":"10.1016\/j.mayocp.2021.04.025_bib75","doi-asserted-by":"crossref","first-page":"1898","DOI":"10.1111\/all.13802","article-title":"Eosinophils capture viruses, a capacity that is defective in asthma","volume":"74","author":"Sabogal Pi\u00f1eros","year":"2019","journal-title":"Allergy"},{"issue":"4","key":"10.1016\/j.mayocp.2021.04.025_bib76","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1164\/rccm.201803-0461OC","article-title":"Anti\u2013IL-5 in mild asthma alters rhinovirus-induced macrophage, B-cell, and neutrophil responses (MATERIAL). A placebo-controlled, double-blind study","volume":"199","author":"Sabogal Pi\u00f1eros","year":"2019","journal-title":"Am J Respir Crit Care Med"},{"issue":"9","key":"10.1016\/j.mayocp.2021.04.025_bib77","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1136\/thoraxjnl-2014-205465","article-title":"Toll-like receptor 7 governs interferon and inflammatory responses to rhinovirus and is suppressed by IL-5\u2013induced lung eosinophilia","volume":"70","author":"Hatchwell","year":"2015","journal-title":"Thorax"},{"issue":"12","key":"10.1016\/j.mayocp.2021.04.025_bib78","doi-asserted-by":"crossref","first-page":"1645","DOI":"10.1513\/AnnalsATS.202006-613RL","article-title":"Asthma in COVID-19 hospitalizations: an overestimated risk factor?","volume":"17","author":"Broadhurst","year":"2020","journal-title":"Ann Am Thorac Soc"},{"issue":"4","key":"10.1016\/j.mayocp.2021.04.025_bib79","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1016\/j.jaci.2018.06.002","article-title":"A\u00a0bispecific antibody strategy to target multiple type 2 cytokines in asthma","volume":"142","author":"Godar","year":"2018","journal-title":"J\u00a0Allergy Clin Immunol"},{"issue":"3","key":"10.1016\/j.mayocp.2021.04.025_bib80","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1016\/j.jaci.2012.07.025","article-title":"Human versus mouse eosinophils: \"that which we call an eosinophil, by any other name would stain as red\"","volume":"130","author":"Lee","year":"2012","journal-title":"J\u00a0Allergy Clin Immunol"}],"container-title":["Mayo Clinic Proceedings"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0025619621004067?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0025619621004067?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,21]],"date-time":"2025-09-21T01:37:18Z","timestamp":1758418638000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0025619621004067"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10]]},"references-count":80,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2021,10]]}},"alternative-id":["S0025619621004067"],"URL":"https:\/\/doi.org\/10.1016\/j.mayocp.2021.04.025","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.740839317.793592752","asserted-by":"object"}]},"ISSN":["0025-6196"],"issn-type":[{"value":"0025-6196","type":"print"}],"subject":[],"published":{"date-parts":[[2021,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Eosinophils in Health and Disease: A State-of-the-Art Review","name":"articletitle","label":"Article Title"},{"value":"Mayo Clinic Proceedings","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.mayocp.2021.04.025","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Mayo Foundation for Medical Education and Research. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}